.png)
choness/iStock via Getty Images
- Teleflex Incorporated (NYSE:TFX) said that it completed the previously announced acquisition of the Vascular Intervention business of BIOTRONIK SE.
- Since the Vascular Intervention acquisition was completed earlier than anticipated, the company now projects that the acquired products will bring in €177M, in revenue in the second half of 2025.
More on Teleflex
- Teleflex: Cheap With Significant Unknowns
- Teleflex Incorporated (TFX) Q1 2025 Earnings Call Transcript
- Teleflex outlines growth strategy with 6% projection for RemainCo and BIOTRONIK acquisition
- Teleflex Non-GAAP EPS of $2.91 beats by $0.03, revenue of $700.7M beats by $1.33M
- Seeking Alpha’s Quant Rating on Teleflex
English (US) ·